Publicacións en colaboración con investigadores/as de Hospital Universitario Reina Sofia (9)

2023

  1. Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study

    Cancers, Vol. 15, Núm. 21

  2. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    European Urology, Vol. 82, Núm. 2, pp. 212-222

2020

  1. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Therapeutic Advances in Medical Oncology, Vol. 12

2018

  1. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

    BMC Pharmacology and Toxicology, Vol. 19, Núm. 1

2017

  1. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

    European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

2013

  1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

  2. Zoledronic acid in genitourinary cancer

    Clinical and Translational Oncology, Vol. 15, Núm. 11, pp. 871-878